Three-drug regimen improves survival in advanced head and neck cancers

ATLANTA--The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination, researchers from Dana-Farber Cancer Institute in Boston will report at the American Society of Clinical Oncology's annual meeting in Atlanta.

The survival advantage emerged from an international clinical trial of more than 500 patients with squamous cell carcinoma of the head and neck treated with a sequential regimen that included induction chemotherapy and chemoradiotherapy, explains Marshall R. Posner, MD, director of head and neck oncology at Dana-Farber.

"This changes the standard of care for chemotherapy and radiation for head and neck cancer in this country," says Posner, who will present the data at a scientific special session on head and neck cancers on Sunday, June 4, 1 p.m., Building C, Level 1, Hall C4.

In recent years, Posner and colleagues at Dana-Farber have developed a multi-modality therapy for inoperable, locally advanced head and neck cancers that can reduce the need to remove critical organs while giving the patient good odds of survival. The first phase is induction chemotherapy with a combination of drugs followed by simultaneous fractionated radiation therapy and weekly treatment with carboplatin chemotherapy. Patients then have surgery if needed.

A combination of cisplatin and fluorouracil (5-FU) has been used for the induction chemotherapy. Posner's team has added docetaxel (Taxotere) as a third drug, and the clinical trial compared the three-drug versus the two-drug regimen. From 1999 to 2003, a total of 538 patients were randomized to the two treatments; 501 patients were evaluable. The patients were followed for at least two years, and 79 percent were followed for three years.

Survival estimates for three years showed that the addition of docetaxel reduced the r

Contact: Bill Schaller
Dana-Farber Cancer Institute

Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Lung cancer screening regimen provides opportunity for cure
3. Response to anti-HIV therapy improved if treatment begins six months after preventive regimen
4. Important factors in compliance with HIV regimens identified; and more
5. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
6. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
7. Dose-dense chemotherapy for early breast cancer found safe, similar to standard regimen
8. Lancet study: Pfizers Vfend equals two-drug candidemia regimen, with fewer serious side effects
9. Treatment regimen offers greater survival advantage for recurrent head and neck cancers
10. Steroid-free regimen with CellCept found comparable to standard therapy in liver transplantation
11. Breast cancer chemotherapy regimen associated with life-threatening complications

Post Your Comments:

(Date:7/2/2020)... ... July 02, 2020 , ... ... treatment of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop ... time. , While vitiligo is equally prevalent in all ethnic groups, ...
(Date:7/2/2020)... ... 02, 2020 , ... Columbia Southern University (CSU), a leading ... to Eric Simmons of Temecula, California. , CSU’s occupational safety and health ... master’s degree in occupational safety and health from the university, is the corporate ...
(Date:7/2/2020)... ... July 02, 2020 , ... The Coronavirus (COVID-19) pandemic ... work. In conjunction with the American Dental Association and Centers for Disease Control ... , Due to safety concerns, the announcement sparked hesitancy among some hygienists, ...
(Date:7/1/2020)... ... 01, 2020 , ... ABSTRAX, an industry leader in the ... new terpene infused product line including custom rolling papers, cones, flat wraps, and ... and flavors worldwide. , “We’ve made it easier than ever for brands to ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... that Doug Salvador, MD, Associate Professor of Medicine at the University of Massachusetts ... and Safety Strategies, LLC have joined the SIDM Board of Directors. Dr. Salvador ...
Breaking Medicine News(10 mins):
(Date:7/1/2020)... ... 2020 , ... Dexur’s analysis of medicare claims of hospitals within a 25-mile ... Southwest General Health Center , and Lutheran Hospital had the best ... value analysis tracks a patient’s episode of care from the date of admission for ...
(Date:6/28/2020)... ... June 28, 2020 , ... Probiotics have ... substantiate the effectiveness of oral-care probiotics to maximize teeth and gum health. ... behind both is simple – utilizing naturally occurring positive bacteria to improve health ...
(Date:6/25/2020)... ... June 25, 2020 , ... Billon Group received a ... distributed ledger platform to store COVID-19 related certificates to support workers’ safe return ... functioning prototype for publishing, sharing and verifying a wide array of workplace training ...
Breaking Medicine Technology:
Cached News: